• Home
  • About us
  • Log-In
  • Join Us
  • Sitemap
  • Recruit
ǰ/ Q&A
ڷû
Ŭ
A/S
Ŭ ȸ
 ǰȳ  м    žళ Ž

ADME-Tox Assay

๰ Absorption, Distribution, Metabolism, Excretion (ADME) Pharmacokinetics (PK) ϱ ʼ ũ ׸Դϴ.

Eurofins Discovery
ǰ ϱ
μϱ






Cat. No. Service Target
METABOLIC STABILITY
STABILITY - LIVER MICROSOMES
0607 Intrinsic clearance (liver microsomes, human)
0794 Intrinsic clearance (liver microsomes, rat, Sprague-Dawley)
0806 Intrinsic clearance (liver microsomes, mouse, CD-1)
0793 Intrinsic clearance (liver microsomes, dog, Beagle)
0792 Intrinsic clearance (liver microsomes, monkey, Cynomolgus)
2227 Metabolic stability (liver microsomes, non-standard) 
STABILITY - HEPATOCYTES
1432 Intrinsic clearance (cryopreserved hepatocytes, human)
1435 Intrinsic clearance (cryopreserved hepatocytes, rat, Sprague-Dawley)
1436 Intrinsic clearance (cryopreserved hepatocytes, mouse, CD-1)
1434 Intrinsic clearance (cryopreserved hepatocytes, dog, Beagle)
1433 Intrinsic clearance (cryopreserved hepatocytes, monkey, Cynomolgus)
3006 Metabolic stability (cryopreserved hepatocytes, non-standard)  
STABILITY - liver S9
0634 Intrinsic clearance (liver S9, human)
1395 Intrinsic clearance (liver S9, rat, Sprague-Dawley) 
1396 Intrinsic clearance (liver S9, dog, Beagle) 
1397 Intrinsic clearance (liver S9, mouse, CD-1) 
1398 Intrinsic clearance (liver S9, monkey, Cynomolgus) 
3357 Intrinsic clearance (liver S9, non-standard) 
CYP INHIBITION
CYP INHIBITION – DRUG SUBSTRATE - HLM
G232 CYP inhibition (HLM, package of 8 assays)
2064 CYP1A inhibition (HLM, phenacetin substrate)
2065 CYP2B6 inhibition (HLM, bupropion substrate)
2244 CYP2C8 inhibition (HLM, paclitaxel substrate)
4481 CYP2C8 inhibition (HLM, amodiaquine substrate)
2066 CYP2C9 inhibition (HLM, diclofenac substrate)
1772 CYP2C19 inhibition (HLM, omeprazole substrate)
1838 CYP2D6 inhibition (HLM, dextromethorphan substrate)
1770 CYP3A inhibition (HLM, midazolam substrate)
1769 CYP3A inhibition (HLM, testosterone substrate)
CYP INHIBITION – FLUOROGENIC SUBSTRATE
G233 CYP inhibition (fluorogenic substrates, package of 8 assays)
0389 CYP1A2 inhibition (recombinant, CEC substrate)
0415 CYP2B6 inhibition (recombinant, EFC substrate)
1201 CYP2C8 inhibition (recombinant, DBF substrate)
0412 CYP2C9 inhibition (recombinant, MFC substrate)
0390 CYP2C19 inhibition (recombinant, CEC substrate)
1338 CYP2D6 inhibition (recombinant, MFC substrate)
0391 CYP3A4 inhibition (recombinant, BFC substrate)
0939 CYP3A4 inhibition (recombinant, BzRes substrate)
CYP INHIBITION - TIME DEPENDENT
G234 Time-dependent CYP inhibition (HLM, package of 10 assays)
G197 Time-dependent CYP1A inhibition (HLM, phenacetin substrate)
G199 Time-dependent CYP2C9 inhibition (HLM, diclofenac substrate)
G198 Time-dependent CYP2C19 inhibition (HLM, omeprazole substrate)
G200 Time-dependent CYP2D6 Inhibition (HLM, dextromethorphan substrate)
G201 Time-dependent CYP3A inhibition (HLM, midazolam substrate)
CYP INDUCTION
CYP INDUCTION - mRNA
3860 CYP1A2 induction (human hepatocytes, mRNA level, 1 donor)
3861 CYP2B6 induction (human hepatocytes, mRNA level, 1 donor)
3864 CYP3A4 induction (human hepatocytes, mRNA level, 1 donor)
3862 CYP1A2 induction (human hepatocytes, mRNA level, 3 donors)
3863 CYP2B6 induction (human hepatocytes, mRNA level, 3 donors)
3865 CYP3A4 induction (human hepatocytes, mRNA level, 3 donors)
PERMEABILITY
PERMEABILITY - CACO-2
3318 A-B permeability (Caco-2, pH 6.5/7.4)
3319 A-B permeability (Caco-2, pH 7.4/7.4)
3320 B-A permeability (Caco-2, pH 6.5/7.4)
3321 B-A permeability (Caco-2, pH 7.4/7.4)
3325 A-B permeability (Caco-2, pH 7.4/7.4 + verapamil) 
3326 B-A permeability (Caco-2, pH 7.4/7.4 + verapamil) 
3644 A-B permeability (Caco-2, non-standard) 
3645 B-A permeability (Caco-2, non-standard) 
4482 A-B permeability (Caco-2 pH 7.4/7.4 + Ko143) 
4483 B-A permeability (Caco-2 pH 7.4/7.4 + Ko143)
4560 A-B permeability (Caco-2, pH 7.4/7.4 + MK571) 
4561 B-A permeability (Caco-2, pH 7.4/7.4 + MK571) 
G206 P-gp substrate assessment (Caco-2)
G235 Bidirectional permeability (Caco-2, pH 6.5/7.4)
G236 Bidirectional permeability (Caco-2, pH 7.4/7.4)
G330 BCRP substrate assessment (Caco-2)
G336 MRP2 substrate assessment (Caco-2)
G357 Caco-2 Efflux Transporter Substrate Panel
SOLUBILITY
SOLUBILITY - HPLC
G228 Aqueous solubility (PBS, SGF, SIF)
0435 Aqueous solubility (PBS, pH 7.4)
4537 Aqueous solubility (nephelometry)
3646 Aqueous solubility (nephelometry, HBSS, pH 7.4)
3377 Aqueous solubility (nephelometry, non-standard) 
3427 Aqueous solubility (nephelometry, PBS, pH 7.4)
2073 Aqueous solubility (non-standard)
PROTEIN BINDING
736 Protein binding (serum albumin, human)
2194 Protein binding (plasma, human)
2222 Protein binding (plasma, rat, Sprague-Dawley)
2223 Protein binding (plasma, mouse, CD-1)
2224 Protein binding (plasma, dog, Beagle)
2225 Protein binding (plasma, monkey, Cynomolgus)
2513 Protein binding (non-standard)
4780 Protein binding (plasma, mini-pig)
DRUG TRANSPORTERS
ABC TRANSPORTERS
1324 P-gp inhibition (MDR1-MDCKII, calcein AM substrate)
3633 BCRP inhibition (BCRP-CHO, Hoechst 33342 substrate)
3878 MRP1 inhibition (MRP1-HEK, Calcein AM substrate)
3879 MRP2 inhibition (MRP2-HEK, CDCFDA substrate)
3880 MRP3 inhibition (MRP3-HEK, CDCFDA substrate)
3745 BSEP inhibition (MV, 3H-taurocholate substrate)
SLC TRANSPORTERS
3660 OATP1B1 inhibition (OATP1B1-CHO, FMTX substrate)
3661 OATP1B3 inhibition (OATP1B3-CHO, FMTX substrate)
3658 OAT1 inhibition (OAT1-CHO, CF substrate)
3659 OAT3 inhibition (OAT3-CHO, CF substrate)
3726 OCT2 inhibition (OCT2-CHO, ASP+ substrate)
3746 OCT1 inhibition (OCT1-CHO, ASP+ substrate)
3656 ASBT inhibition (ABST-CHO, 3H-taurocholic acid substrate)
3657 NTCP inhibition (NTCP-CHO, 3H-taurocholic acid substrate)
4541 MATE1 inhibition (MATE1-HEK, DAPI substrate)
4542 MATE2-K inhibition (MATE2-K-HEK, DAPI substrate)
CYP PHENOTYPING
G230 CYP phenotyping
UGT
UGT PHENOTYPING
G231 UGT1A1 phenotyping
UGT INHIBITION
3763 UGT1A1 inhibition (recombinant, scopoletin substrate)
METABOLITE IDENTIFICATION
METABOLITE IDENTIFICATION
3451 Metabolite identification (liver microsomes, human)
3587 Metabolite identification (liver microsomes, rat, Sprague-Dawley)
3588 Metabolite identification (liver microsomes, mouse, CD-1)
3586 Metabolite identification (liver microsomes, dog, Beagle)
3585 Metabolite identification (liver microsomes, monkey, Cynomolgus)
GLUCURONIDE CONJUGATION
0610 Glucuronide conjugate detection (liver microsomes, human)
1545 Glucuronide conjugate detection (liver microsomes, rat, Sprague-Dawley)
1546 Glucuronide conjugate detection (liver microsomes, mouse, CD-1)
1544 Glucuronide conjugate detection (liver microsomes, dog, Beagle)
1543 Glucuronide conjugate detection (liver microsomes, monkey, Cynomolgus)
GLUTATHIONE CONJUGATION
0530 Glutathione conjugate detection (liver S9, human)
1541 Glutathione conjugate detection (liver S9, rat, Sprague-Dawley)
1542 Glutathione conjugate detection (liver S9, mouse, CD-1)
1540 Glutathione conjugate detection (liver S9, dog, Beagle)
1539 Glutathione conjugate detection (liver S9, monkey, Cynomolgus)
BLOOD STABILITY
1437 Half-life (blood, human)
1440 Half-life (blood, rat, Sprague-Dawley)
1441 Half-life (blood, mouse, CD-1)
1439 Half-life (blood, dog, Beagle)
1438 Half-life (blood, monkey, Cynomolgus)
PLASMA STABILITY
0887 Half-life (plasma, human)
0888 Half-life (plasma, rat, Sprague-Dawley)
0923 Half-life (plasma, mouse, CD-1)
0924 Half-life (plasma, dog, Beagle)
0948 Half-life (plasma, monkey, Cynomolgus)
BLOOD PARTITIONING
1371 Blood partitioning (human)
1374 Blood partitioning (rat, Sprague-Dawley)
1375 Blood partitioning (mouse, CD-1)
1373 Blood partitioning (dog, Beagle)
1372 Blood partitioning (monkey, Cynomolgus)
PARTITION COEFFICIENT
0417 Partition coefficient (log D, n-octanol/PBS, pH 7.4)